27 November 2020 | NewsCOVID-19 vaccines: Frequently asked questionsRead the full article
From 1 July 2020 some important changes to the National Immunisation Program (NIP) and recommendations for pneumococcal, meningococcal and hepatitis A vaccination will take effect.
The pneumococcal vaccination recommendations and schedule will change to reflect the current best clinical evidence in preventing pneumococcal disease in adults and in people with conditions that increase their risk of disease. The changes seek to simplify vaccination advice by making it easier to understand who should get vaccinated, and when and which vaccine they should get.
The meningococcal vaccinations funded through the NIP will change to better protect Aboriginal and Torres Strait Islander children and people of all ages with medical conditions that increase their risk of invasive meningococcal disease. The NIP schedule for hepatitis A vaccination for Aboriginal and Torres Strait Islander children in the Northern Territory, Queensland, South Australia and Western Australia will also be modified.
Learn what you need to know about these upcoming NIP changes in this next NCIRS webinar.
The webinar will be recorded and will be available on the NCIRS website in the days following.
Register here to view live via Zoom webinar
Dr Clayton Chiu
Associate Director, Immunisation Policy Support and Guideline Development, NCIRS, Public Health Physician
Clayton Chiu is a public health physician, trained in adult internal medicine and public health. He is also a conjoint lecturer of The Children’s Hospital at Westmead Clinical School, The University of Sydney. His main interests are in the epidemiology and control of communicable diseases; immunisation for prevention and control of vaccine preventable diseases; and knowledge translation to support development of population vaccination policies. Dr Chiu leads the Research to inform policy program at NCIRS providing scientific research support to the Immunisation Branch of the Australian Government Department of Health and ATAGI, particularly for the development and implementation of national immunisation policies.
Associate Professor Christopher Blyth Co-Director, Wesfarmers Centre of Vaccines and Infectious Diseases, Paediatric Infectious Diseases Physician and Clinical Microbiologist
Dr Chris Blyth is a clinical academic and NHMRC Emerging Leadership Fellow. He is Associate Professor of Paediatrics, University of Western Australia and Co-director of Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute. He leads the Department of Paediatric Infectious Diseases at Perth Children's Hospital. The majority of his research is in influenza, vaccine-preventable respiratory tract infection, pneumonia and vaccine safety.
Dr Blyth was appointed as a sitting member of the Australian Technical Advisory Group on Immunisation (ATAGI) in 2012, Australia’s peak immunisation advisory group to Government, assuming the role of deputy chair in 2014 and co-chair in 2018. He is part of the Expert Leadership Group of AusVaxSafety, the Scientific Steering Committee of the Human Vaccines Program and was recently appointed as an Associate Member of the Australian Academy of Health and Medical Science.
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Copyright © 2021 NCIRS. All rights reserved
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS